News Pfizer claims FDA okay for rare heart disease drug tafamidis The FDA has given a green light to two formulations of Pfizer’s tafamidis that have become the first drugs to be approved in the US for cardiomyopathy associated with rare disease transthyr
News Pfizer set for July FDA verdict on rare heart disease drug Pfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after it first reached the market in Europe.
News Pfizer drug reduces mortality in patients with fatal heart d... Pfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase 3 trial.
News Better slashes staff in another digital health retreat Company will cut its headcount by 35%, as it waits for an FDA decision on its diabetes DTx.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
